Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED)

NCT00809302 is registered in ClinicalTrials.gov with Neurogen Corporation as lead sponsor.

NCT NCT00809302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00809302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED)
Lead sponsor
Neurogen Corporation
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2008
Completion date
October 31, 2009
Enrollment
9 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

early parkinson disease